Nurix Therapeutics, Inc.

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +12.8% (SPY −2.6%, XLV +9.9%). 3 months: +4.6% (SPY −2.2%, XLV +13.5%). 1 year: +104.6% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: NRIX, SPY and XLV · as of 3 Nov 2026

2. 02

   9.2 days to cover short interest

   20.6M shares were sold short at the 15 Oct 2026 settlement, 18.9% of the 109.2M shares outstanding; covering them would take 9.2 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

3. 03

   8.5% below its 52-week high

   Closed at $25.82 on 3 Nov 2026: 8.5% below the 52-week high of $28.23 (19 Aug 2026) and 121.3% above the low of $11.67 (7 Nov 2025).

   Daily price bars, split-adjusted · as of 3 Nov 2026

4. 04

   Volume 1.9× its 30-session average on 3 Nov 2026

   3 Nov 2026 volume of 4.4M shares was 1.9× the average of the 30 sessions before it (2.3M), as the price rose 0.5%. SPY traded 0.8× its own average that session.

   Daily volume against a 30-session baseline · as of 3 Nov 2026

5. 05

   Above its 50- and 200-day averages

   The 3 Nov 2026 close of $25.82 was 3.5% above its 50-day average ($24.95) and 27.5% above its 200-day average ($20.24). It has closed above the 200-day for 104 sessions, since 8 Jun 2026. The 50-day average crossed above the 200-day on 1 Dec 2025, 232 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

At the 3 Nov 2026 close